PARP2 downregulation in T cells ameliorates lipopolysaccharide-induced inflammation of the large intestine.
Fiche publication
Date publication
juin 2023
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DANTZER Françoise
Tous les auteurs :
Bencsics M, Bányai B, Ke H, Csépányi-Kömi R, Sasvári P, Dantzer F, Hanini N, Benkő R, Horváth EM
Lien Pubmed
Résumé
T cell-dependent inflammatory response with the upregulation of helper 17 T cells (Th17) and the downregulation of regulatory T cells (Treg) accompanied by the increased production of tumor necrosis alpha (TNFa) is characteristic of inflammatory bowel diseases (IBD). Modulation of T cell response may alleviate the inflammation thus reduce intestinal damage. Poly(ADP-ribose) polymerase-2 (PARP2) plays role in the development, differentiation and reactivity of T cell subpopulations. Our aim was to investigate the potential beneficial effect of T cell-specific PARP2 downregulation in the lipopolysaccharide (LPS) induced inflammatory response of the cecum and the colon.
Mots clés
IBD - inflammatory bowel disease, PARP (poly(ADP-ribose) polymerase, PARP2, T lymphocyte, colitis, regulatory (Treg) cell
Référence
Front Immunol. 2023 06 30;14:1135410